The administration of an IκB-ubiquitin ligase inhibitor, pyrrolidine dithiocarbamate (PDTC) [213], to wildtype β-TrCP1 myeloma tumor-bearing mice reduces tumor burden in the bone. Here, BTRC is linked to neoplasm.